139 results
6-K
EX-1
BLRX
Bioline Rx Ltd
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
of stem cells using the mobilization agent plerixafor is the current strategy to collect HSCs for SCD gene therapies, however limitations exist including
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
, we have an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions.
We seek to develop and commercialize a pipeline … success. Our strategy includes commercializing our therapeutic candidates by way of out-licensing arrangements with biotechnology and pharmaceutical
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
of motixafortide for patients with sickle cell disease and pancreatic cancer. In addition, we have an off-strategy, legacy therapeutic product called BL-5010 … candidates that we believe exhibit a high probability of therapeutic and commercial success. Our strategy includes commercializing our therapeutic
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
or significant changes in a licensee’s business strategy may adversely affect the licensee’s willingness or ability to complete its obligations under any … to terminate the Agalimmune Development Agreement effective March 15, 2024.
An important element of our strategy is maintaining relationships
F-3
rbxii
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
7s2cvgn17 zf03
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
bjqted9lj54
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
eyitb 61l
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
zluwbatkg1mgg
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
4frsmcu b6wia6j9hu
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
prl7 84sy87b
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
luzwwq1mqveuma56d79g
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
zb28w4sqblo8q2zfh
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
424B5
ssl2smkutogyg4yp 8p
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
sts7856 wn
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
ijbgpsr
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
sj00y7aw7lb hn
16 Jun 22
BioLineRx Announces Appointment of Commercial Strategy
7:05am
6-K
EX-99
kk38p1yorjaz0513cv
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-99
7okqtxu 7s94rf1tse6
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am